

CURRENT REPORT 7/2023

January 23rd, 2022

Announcement of the NDS on registration of series J shares with the NDS

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Issuer"), with reference to current report No. 5/2023 and current report No. 6/2023 of January 20th, 2023 informs that on January 23rd, 2023 the National Depository for Securities (in Polish: Krajowy Depozyt Papierów Wartościowych) issued an announcement informing of the registration on January 25th, 2023 in the depository for securities of 4,764,674 (four million seven hundred sixty-four thousand six hundred seventy-four) series J ordinary bearer shares of the Issuer with a nominal value of PLN 0.40 each ("Series J Shares") under ISIN code PLSELVT00013.

Thus, the condition for the introduction of Series J Shares to trading on the main market of the Warsaw Stock Exchange on January 25th, 2023 was fulfilled.

Legal basis: Article 56.1.2 of the Act on Public Offering, Current and periodic information

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board